Insulinlike growth factor-I

Current Opinion in Endocrinology and Diabetes

Volumn 3, Issue 4, 1996, Pages 335-345

  Grant, Maria ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 1842423003     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199608000-00009     Document Type: Article

References (111)

1. Sara VR, Hall K: Insulin-like growth factors and their binding proteins. Physiol Rev 1990, 70:591-614.
2. Stiles CD, Capone GT, Scher CD, Antoniades HN, Van Wyk JJ, Pledger WJ: Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc Natl Acad Sci U S A 1979, 76:1279-1283.
3. King GL, Buzney SM, Kahn CR: Differential responsiveness to insulin of endothelial and support cells from micro- and macrovessels. J Clin Invest 1983, 71:974-979.
4. Jialal I, King GL, Buchwald S, Kahn CR, Crettaz M: Processing of insulin by bovine endothelial cells in culture: internalization without degradation. Diabetes 1984, 33:794-800.
5. Hachiya HL, Carpentier JL, King GL: Comparative studies on insulin-like growth factor II and insulin processing by vascular endothelial cells. Diabetes 1986, 35:1065-1072.
6. Clemmons DR: IGF binding proteins: regulation of cellular actions. Growth Regul 1992, 2:80-87.
7. Kiefer MC, Schmid C, Waldvogel M, Schlapfer I, Futo E, Masiarz FR, Green K, Barr PJ, Zapf J: Recombinant human insulin-like growth factor binding proteins 4, 5, and 6: biological and physiochemical characterization. Growth Regul 1993, 3:56-59.
8. Blat C, Delbe J, Villaudy J, Chatelain G, Golde A, Harel L: Inhibitory diffusible factor 45 bifunctional activity: as a cell growth inhibitor and as an insulin-like growth factor I-binding protein. J Biol Chem 1989, 264:12449-12454.
9. Mohan S, Bautista CM, Wergedal J, Baylink DJ: Isolation of inhibitory Insulin-like growth factor (IGF) binding protein from bone cell-conditioned medium: a potential local regulator of IGF action. Proc Natl Acad Sci U S A 1989, 86:8338-8342.
10. Blum WF, Jenne EW, Reppin F, Kietzmann K, Ranke MB, Biench JR: Insulin-like growth factor I (IGF-I) -binding protein complex is a better mitogen than free IGF-I. Endocrinology 1989, 125:766-772.
11. Fowlkes JL, Suzuki K, Nagase H, Thrailkill KM: Proteolysis of insulin-like growth factor binding protein-3 during rat pregnancy: a role for matrix metalloproteinases. Endocrinology 1994, 135:2810-2813.
12. Bourner MJ, Busby WH Jr, Siegel NR, Krivi GG, McCusker RH, Clemmons DR: Cloning and sequence determination of bovine insulin-like growth factor binding protein-2 (IGFBP-2): comparison of its structural and functional properties with IGFBP-1. J Cell Biochem 1992, 48:215-226.
13. Burch WM, Correa J, Shively JE, Powell DR: The 25-kilodalton insulin-like growth factor (IGF)-binding protein inhibits both basal and IGF-I-binding protein inhibits both basal and IGF-I-mediated growth of chick embryo pelvic cartilage in vitro. J Clin Endocrinol Metab 1990, 70:173-180.
14. Andress DL, Loop SM, Zapf J, Kiefer MC: Carboxy-truncated insulin-like growth factors binding protein-5 stimulates mitogenesis in osteoblast-like cells. Biochem Biophys Res Commun 1993, 195:25-30.
15. Elgin RG, Bushby WJJ, Clemmons DR: An insulin-like growth factor (OIGF) binding protein enhances the biological response to IGF-I. Proc Natl Acad Sci U S A 1987, 84:3254-3258.
16. Liu L, Brinkman A, Blat C, Harel L: IGFBP-1, an insulin like growth factor binding protein, is a cell growth inhibitor. Biochem Biophys Res Commun 1991, 174:673-679.
17. Clemmons DR: Interaction of circulating cell-derived and plasma growth factors in stimulating cultured smooth muscle cell replication. J Cell Physiol 1984, 121:425-430.
18. Hansson HA, Brandsten C, Lossing C, Petruson K: Transient expression of insulin-like growth factor I immunoreactivity by vascular cells during angiogenesis. Exp Mol Pathol 1989, 50:125-138.
19. Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Pepine CJ: Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells: a potential treatment for restenosis? Circulation 1994, 89:1511-1517.
20. Bar RS, Boes M: Distinct receptors for IGF-I, IGF-II, and insulin are present on bovine capillary endothelial cells and large vessel endothelial cells. Biochem Biophys Res Commun 1984, 124:203-209.
21. Cohick WS, Gockerman A, Clemmons DR: Vascular smooth muscle cells synthesize two forms of insulin-like growth factor binding proteins which are regulated differently by the insulin-like growth factors. J Cell Physiol 1993, 157:52-60.
22. Giannella-Neto D, Kamyar A, Sharifi B, Pirola CJ, Kupfer J, Rosenfeld RG, Forrester JS, Fagin JA: Platelet-derived growth factor isoforms decrease insulin-like growth factor I gene expression in rat vascular smooth muscle cells and selectively stimulate the biosynthesis of insulin-like growth factor bindind protein 4. Circ Res 1992, 71:646-656.
23. Kamyar A, Pirola CJ, Wang HM, Sharifi B, Mohan S, Forrester JS, Fagin JA: Expression and insulin-like growth factor-dependent proteolysis of insulin-like growth factor-binding protein-4 are regulated by cell confluence in vascular smooth muscle cells. Circ Res 1994, 74:576-585.
24. Taylor WR, Nerem RM, Alexander RW: Polarized secretion of IGF-I and IGF-I binding protein activity by cultured aortic endothelial cells. J Cell Physiol 1993, 154:139-142.
25. Grant MB, Ellis EA, Caballero S: Plasminogen activator inhibitor-1 overexpression in nonproliferative diabetic retinopathy. Exp Eye Res 1996, in press.
26. Pfeifle G, Ditschuenit H: Receptors for insulin and insulin like growth factor in cultured arterial smooth muscle cells depend on their growth state. J Endocrinol 1983, 96:251-257.
27. Grant MB, Wargovich TJ, Ellis EA, Tarnuzzer R, Caballero S, Rossing M, Spoerri PE: Expression of insulin-like growth factor-I, IGF-I receptor and IGF-binding protein-2 and -4 in human atherectomy specimens. 10th International Congress of Endocrinology 1996, 1:273.
28. Parker A, Gockerman A, Busby WH, Clemmons DR: Properties of an insulin-like growth factor-binding protein-4 protease that is secreted by smooth muscle cells. Endocrinology 1995, 136:2470-2475.
29. Nagase H, Okada Y, Suzuki K, Enghild JJ, Salvesen G: Substrate specificities and activation mechanisms of matrix metalloproteinases. Biochem Soc Trans 1991, 19:715-718.
30. Galis Z, Sukhova G, Lark W, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503.
31. Banskota NK, Taub R, Zellner K, King GL: Insulin, insulin-like growth factor I and platelet-derived growth factor interact additively in the induction of the protooncogene c-myc and cellular proliferation in cultured bovine aortic smooth muscle cells. Mol Endocrinol 1989 3:1183-1190.
32. Delafontaine P, Lou H, Alexander RW: Regulation of insulin-like growth factor I messenger RNA levels in vascular smooth muscle cells. Hypertension 1991, 18:742-747.
33. Andronico G, Mangano MT, Nardi E, Mule G, Piazza G, Cerasola G: Insulin-like growth factor 1 and sodium-lithium countertransport in essential hypertension and in hypertensive left ventricular hypertrophy. J Hypertens 1993, 11:1097-1101.
34. Oppenheimer MJ, Sundquist K, Bierman EL: Downregulation of high-density lipoprotein receptor in human fibroblasts by insulin and IGF-I. Diabetes 1989, 38:117-122.
35. Merimee TJ, Fineberg SE, McKusick VA, Hall J: Diabetes mellitus and sexual ateliotic dwarfism: a comparative study. J Clin Invest 1970, 49:1096-1102.
36. Califf RM, Fortin DF, Frid DJ, Harlan W, Ohman EM, Bengtson JR, Nelson CL, Tcheng JE, Mark DB, Stack RS: Restenosis after coronary angioplasty: an overview. J Am Coll Cardiol 1991, 17(6 Suppl B).
37. Deligonul U, et al.: Repeat coronary angioplasty for restenosis: results and predictors of follow-up clinical events. Am Heart J 1989, 117:997-1002.
38. Lambert M, et al.: Multiple coronary angioplasty: a model to discriminate systemic and procedural factors related to restenosis. J Am Coll Cardiol 1988, 12:310-314.
39. King GL, Goodman AD, Buzney S, Moses A, Kahn CR: Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest 1985, 75:1028-1036.
40. Michaelson I: The mode of development of retina vessels. Trans Ophthal Soc UK 1948, 68:137-180.
41. Poulsen J: The Houssay phenomenon in man: recovery from retinopathy in a case of diabetes with Simmonds' disease. Diabetes 1953, 2:7-12.
42. Wright AD, Kohner EM, Oakley NW, Hartog M, Joplin GF, Fraser TR: Serum growth hormone levels and the response of diabetic retinopathy to pituitary ablation. BMJ 1969, 2:346-348.
43. Sonksen PH, Russell-Jones D, Jones RH: Growth hormone and diabetes mellitus: a review of sixty-three years of medical research and a glimpse into the future? Horm Res 1993, 40:68-79.
44. Kohner EM, Oakley NW: Diabetic retinopathy. Metabolism 1975, 24:1085-1102.
45. Passa P, Luyckx AS, Carpentier JL, Lefebvre PJ, Canivet J: Glucagon secretion in diabetic patients with idiopathic haemochromatosis. Diabetologia 1977, 13:509-513.
46. Hansen AP: Abnormal serum growth hormone response to exercise in juvenile diabetics. J Clin Invest 1970, 49:1467-1478.
47. Johansen K, Hansen AP: Diurnal serum growth hormone levels in poorly and well-controlled juvenile diabetics. Diabetes 1971, 20:239-245.
48. Sonksen PH: Growth hormone and cortisol responses to insulin infusion in patients with diabetes mellitus. Lancet 1972, ii:155-160.
49. Sharp PS: Growth hormone responses to hyperinsulinemia in insulin-dependent diabetics: comparison of patients with and without retinopathy. Diabetic Med 1984, 1:55-65.
50. Owens DR: Retinopathy in newly presenting non-insulin-dependent (type 2) diabetic patients. Diabetes Res 1988, 9:59-65.
51. Sundkvist G, Lilia B, Almer LO: Absent elevations in growth hormone, factor VIII elevated antigen and plasminogen activator activity during exercise in diabetic patients resistant to retinopathy. Diabetes Res 1988, 7:25-30.
52. Merimee TJ, Zapf J, Froesch ER: Insulin-like growth factors: studies in diabetics with and without retinopathy. N Engl J Med 1983, 309:527-530.
53. Hyer SL, Sharp PS, Brooks RA, Burrin JM, Kohner EM: A two-year follow-up study of serum insulinlike growth factor-I in diabetics with retinopathy. Metabolism 1989, 38:586-589.
54. Dills DG, Moss SE, Klein R, Klein BE: Association of elevated IGF-I levels with increased retinopathy in late-onset diabetes. Diabetes 1991, 40:1725-1730.
55. Amiel SA, et al.: Effect of diabetes and its control on insulin-like growth factors in the young subject with type I diabetes. Diabetes 1984, 33:1175-1179.
56. Lamberton RP, Goodman AD, Kassoff A, Rubin CL, Treble DH, Daba TM, Merimee TJ, Dadds WJ: Von Willebrand factor (VIII R:Ag), fibronectin, and insulin-like growth factors I and II in diabetic retinopathy and nephropathy. Diabetes 1984, 33:125-129.
57. Tan K, Baxter RC: Serum insulin-like growth factor I levels in adult diabetic patients: the effect of age. J Clin Endocrinol Metab 1986, 63:651-655.
58. Chen CH, Chen SC: Angiogenic activity of vitreous and retinal extract. Invest Ophthalmol Vis Sci 1980, 19:596-602.
59. Grant MB, Guay C, Lottenberg R: Desmopressin stimulates parallel norepinephrine and tissue plasminogen activator release in normal subjects and patients with diabetes mellitus. Thromb Haemost 1988, 59:269-272.
60. Meyer-Schwickerath R, Pfeiffer A, Blum WF, Freyberger H, Klein M, Losche C, Rollmann R, Schatz H: Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease: studies in nondiabetic and diabetic subjects. J Clin Invest 1993, 92:2620-2625.
61. Danias J, Stylianopopulou F: Expression of IGF-I and IGF-II genes in the adult rat eye. Curr Eye Res 1990, 9:379-386.
62. Grant MB, Guay C: Plasminogen activator production by human retinal endothelial cells of nondiabetic and diabetic origin. Invest Ophthalmol Vis Sci 1991, 32:53-64.
63. Grant MB, Schmetz I, Russell B, Harwood H Jr., Silverstein J, Merimee TJ: Changes in insulin-like growth factors I and II and their binding protein after a single intramuscular injection of growth hormone. J Clin Endocrinol Metab 1986, 63:981-984.
64. Arnold DR, Moshayedi P, Schoen TJ, Jones BE, Chader GJ, Waldbillig RJ: Distribution of IGF-I and -II, IGF binding proteins (IGFBPs) and IGFBP mRNA in ocular fluids and tissues: potential sites of synthesis of IGFBPs in aqueous and vitreous. Exp Eye Res 1993, 56:555-565.
65. Grant MB, Mames RN, Fitzgerald C, Ellis EA, Caballero S, Chegini N, Guy J: Insulin-like growth factor I as an angiogenic agent: in vivo and in vitro studies. Ann N Y Acad Sci 1993, 692:230-242.
66. Grant MB, Caballero S, Millard WJ: Inhibiiton of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment of neovascularization. Regul Pep 1993, 48:267-278.
67. Frank R: Etiologic mechanisms in diabetic retinopathy. Retina 1994, 1994:1243-1276.
68. Franks WA, Limb GA, Stanford MR, Ogilvre J, Wolstencroft RA, Chignell AH, Damonde DC: Cytokines in human intraocular inflammation. Curr Eye Res 1992, 11:187-191.
69. Edwards CK, Ghiasuddin SM, Schepper AN, Yunger LM, Kelley KW: Newly defined property of somatotropin: priming macrophages for produciton of superoxide anion. Science 1988, 239:769-771.
70. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A: Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988, (240):1546-1548.
71. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H: Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and and aging. Proc Natl Acad Sci U S A 1990, 87:9010-9014.
72. Kirstein M, Aston C, Hintz R, Vlassara H: Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 1992, 90:439-446.
73. Krolewski AS: The changing natural history of nephropath in type I diabetes. Am J Med 1984, (78):785-794.
74. Kostraba JN, Dorman JS, Orchard TJ, Becker DJ, Ohki Y, Ellis D, Doft VH, Lobes LA, LaPorte RE, Drash AL: Contribution of diabetes duration before puberty to development of microvascular complications in IDDM subjects. Diabetes Care 1989, 12:686-693.
75. Sharp PS, Fallon TJ, Brazier OJ, Sandler L, Joplin GF, Kohner EM: Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia 1987, 30:199-207.
76. Salardi S, Cacciari E, Pascucci MG, Giambiasi E, Tacconi M, Tazzari R, Cicognani A, Boriani F, Puglioli R, Mantovani W: Microalbuminuria in diabetic children and adolescents: relationship with puberty and growth hormone. Acta Paediatr Scand 1990, 79:437-443.
77. Doi T, et al.: Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulinlike growth factor-1. Am J Pathol 1988, 131:398-403.
78. Doi T, Striker LJ, Gibson CC, Agodoa LY, Brinster RL, Striker GE: Glomerular lesions in mice transgenic for growth hormone and insulinlike growth factor-I: I: relationship between increased glomerular size and mesangial sclerosis. Am J Pathol 1990, 137:541-552.
79. O'Shea MH, Layish DT: Growth hormone and the kidney: a case presentation and review of the literature. J Am Soc Nephrol 1992, 3:157-161.
80. Conti FG, Striker LJ, Lesniak MA, MacKay K, Roth J, Striker GE: Studies on binding and mitogenic effect of insulin and insulin-like growth factor I in glomerular mesangial cells. Endocrinology 1988, 122:2788-2795.
81. Moran A, Brown DM, Kim Y, Klein DJ: Effects of IGF-I and glucose on protein and proteoglycan synthesis by human fetal mesangial cells in culture. Diabetes 1991, 40:1346-1354.
82. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984, 74:1143-1155.
83. Abrass CK, et al.: Insulin and insulin-like growth factor I binding to cultured rat glomerular mesangial cells. Endocrinology 1988, 123:2432-2439.
84. Arnqvisk HJ, Ballermann BJ, King GL: Receptors for and effects of insulin and IGF-I in rat glomerular mesangial cells. Am J Physiol 1988, 254.
85. Guler HP, Zapf J, Scheiwiller E, Froesch ER: Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats. Proc Natl Acad Sci U S A 1988, 85:4889-4893.
86. Werner H, Shen-Orr Z, Stannard B, Burguera B, Roberts C Jr., LeRoith D: Experimental diabetes increases insulinlike growth factor I and II receptor concentration and gene expression in kidney. Diabetes 1990, 39:1490-1497.
87. Fagin JA, Pixley S, Slanina S, Ong J, Melmed S: Insulin-like growth factor I gene expression in GH3 rat pituitary cells: messenger ribonucleic acid content, immunocytochemistry, and secretion. Endocrinology 1987, 120:2037-2043.
88. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marback P, Petcher JT: SMS 201-995: a very potent and selective octapaptide analogue of somatostatin with prolonged action. Life Sci 1972, 31:1133-1140.
89. Kokudo N, Kothary PC, Eckhauser FE, Raper SE: Inhibitory effects of somatostatin on rat hepatocyte proliferation are mediated by cyclic AMP. J Surg Res 1991, 51:113-118.
90. Setyono-Han B, et al.: Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 1987, 47:1566-1570.
91. Hofland L, van-Koetsveld P, Wouters N, Waaijers M, Reubi J, Lamberts S: Dissociation of antiproliferative and antihormonal effects of the somatostatin analog octreotide on 7315 pituitary tumor cells. Endocrinology 1992, 131:571-577.
92. Heisler S, Reisine TD, Hook VYH, Axelrod J: Somatostatin inhibits multireceptor stimulation of cyclic AMP formation and corticotropin secretion in mouse pituitary tumor cells. Proc Natl Acad Sci U S A 1982, 79:6502-6506.
93. 2+ currents by CHRH and somatostatin in a pituitary cell line. EMBO J 1988, 6:1627-1633.
94. Liebow C, Reilly C, Serrano M, Schally AV: Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phsophatase. Proc Natl Acad Sci U S A 1989, 86:2003-2007.
95. French MB, Moor BC, Lussier BT, Kraicer J: Protein kinase C is not essential for growth hormone (GH)-releasing factor-induced GH release from rat somatotrophs. Endocrinology 1989, 124:2235-2244.
96. Barrie R, Woltering EA, Hajarizadeh H, Mueller C, Ure T, Fletcher WS: Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res 1993, 55:446-450.
97. Woltering EA, Barrie R, O'Dorisio TM, Arce D, Ure T, Cramer A, Holmes D, Robertson J, Fassler J: Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 1991, 50:245-251.
98. Patel PC, Barrie R, Hill N, Landeck S, Kurozawa D, Woltering EA: Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surgery 1994, 116:1148-1152.
99. Yarden Y, Ulrich A: Growth factor receptor tyrosine kinases. Annu Rev Biochem 1988, 57:443-478.
100. Colas B, Cambillau C, Buscail L, Zeggari M, Esteve JP, Lautre V, Thomas F, Vaysse N, Susini C: Stimulation of a membrane tyrosine phosphatase activity by somatostatin analogue in rat pancreatic acinar cells. Eur J Biochem 1992, 207:1017-1024.
101. Lee HK, Suh KI, Koh CS, Min HK, Lee JH, Chung H: Effect of SMS 201-995 in rapidly progressive diabetic retinopathy [letter]. Diabetes Care 1988, 11:441-443.
102. McCombe M, Lightman S, Eckland DJ, Hamilton AM, Lightman SL: Effect of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: a pilot study. Eye 1991, 5:569-575.
103. Mallet B, Vialettes B, Haroche S, Escoffier P, Gastaut P, Taubert JP, Vague P: Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabetes Metab 1992, 18:438-444.
104. Grant MB, Mames R, Cooper R, Caballero S, Fitzgerald C: Octreotide (OCT) does not prevent progression of diabetic retinopathy (DR). Invest Ophthalmol Vis Sci 1995, 37:958.
105. Gerich JE: Use of somatostatin in the study of carbohydrate homeostasis in man: physiologic, pathologic, and therapeutic considerations. Adv Exp Med Biol 1977, 87:299-318.
106. Grant MB, et al.: Octreotide does not prevent progression of diabetic retinopathy. Invest Ophthalmol Vis Sci 1996, 37:S958.
107. Hoeldtke RD, Israel BC: Treatment of orthostatic hypotension with octreotide. J Clin Endocrinol Metab 1989, (68):1051-1059.
108. Tiell ML, Stemerman MB, Spaet TH: The influence of the pituitary on arterial intimai proliferation in the rat. Circ Res 1978, 42:644-649.
109. Santoian ED, Schneider JE, Gravanis MB, Foegh M, Tarazona N, Cipolla GD, King S: Angiopeptin inhibits intimai hyperplasia after angioplasty in porcine coronary arteries. Circulation 1993, 88:11-14.
110. Lundergan CF, Foegh ML, Ramwell PW: Peptide inhibition of myointimal proliferation by angiopeptin, a somatostatin analogue. J Am Coll Cardiol 1991, 17(6 suppl).
111. Eriksen UH, Amtorp O, Bagger JP, Emanuelsson H, Foegh M, Henningsen P, Saunamaki K, Schaeffer M, Thayssen P, Orskoo H: Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty. Am Heart J 1995, 130:1-8.